Statement Of Comprehensive Income [Abstract]

HEMOGENYX PHARMACEUTICALS PLC - Filing #5969073

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Statement of comprehensive income [abstract]
Profit (loss)	6,297 GBP	5,625,478 GBP	- GBP	- GBP	- GBP	- GBP	- GBP	- GBP	5,619,181 GBP	- GBP	- GBP	6,696,493 GBP	5,815 GBP	- GBP	6,690,678 GBP	- GBP	- GBP	- GBP
Other comprehensive income [abstract]
Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]
Exchange differences on translation [abstract]
Gains (losses) on exchange differences on translation of foreign operations, net of tax	—	358,396 GBP	—	—	—	—	—	—	—	—	—	903,067 GBP	—	—	—	—	—	—
Other comprehensive income	- GBP	358,396 GBP	- GBP	- GBP	- GBP	358,459 GBP	- GBP	- GBP	- GBP	- GBP	- GBP	903,067 GBP	- GBP	- GBP	- GBP	903,067 GBP	- GBP	- GBP
Comprehensive income	—	5,983,937 GBP	- GBP	- GBP	- GBP	358,459 GBP	- GBP	- GBP	- GBP	- GBP	- GBP	5,793,426 GBP	—	- GBP	- GBP	903,067 GBP	- GBP	- GBP
Comprehensive income attributable to [abstract]
Comprehensive income, attributable to owners of parent	—	5,977,640 GBP	—	—	—	—	—	—	—	—	—	5,787,611 GBP	—	—	—	—	—	—
Comprehensive income, attributable to non-controlling interests	—	6,297 GBP	—	—	—	—	—	—	—	—	—	5,815 GBP	—	—	—	—	—	—